Clinical Trial

Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group

Study acronym: RADIANCE
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The RADIANCE multicenter, randomized phase II trial will assess the efficacy of durvalumab, a PD-L1 immune checkpoint inhibitor, in combination with primary mitomycin C (MMC)/5-fluorouracil (5-FU)-based radiochemotherapy (RCT) in patients with locally-advanced anal squamous cell carcinoma (ASCC).
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2020-01-13; most recent amendment 2024-09-17.
Status change: Recruiting → Active, Not Recruiting 2023-09-15
Trial Details
NCT Number NCT04230759
Lead Sponsor Goethe University
Conditions Anal Cancer, Anal Carcinoma, Anal Cancer Stage III, Anal Cancer Stage II
Enrollment 180 participants
Start Date 2020-01-07
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-14